Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH4 | Q9H3N8 | 6/20 | 0.37 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.33 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.33 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.33 |
| ▸ | GCK | P35557 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.33 |
| ▸ | AKR1C3 | P42330 | 2/20 | 0.32 |
| ▸ | AKR1C2 | P52895 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5700409 | 0.81 | CHRNA7 (0.46) | HRH4NR1H2ROCK1GCKCHRNA7 | |
| SCHEMBL10920036 | 0.75 | ROCK1 (0.40) | NR1H2ROCK1SMN1; SMN2 | |
| SCHEMBL3465119 | 0.74 | HRH4 (0.40) | HRH4LOXL2ROCK1 | |
| SCHEMBL13801171 | 0.67 | UHRF1 (0.48) | ROCK1SMN1; SMN2 | |
| SCHEMBL25824990 | 0.67 | L3MBTL1 (0.46) | GCKSMN1; SMN2CHRNA7 | |
| SCHEMBL3439349 | 0.67 | CCR1 (0.39) | HRH4NR1H2 | |
| SCHEMBL5700498 | 0.67 | HRH4 (0.39) | HRH4ROCK1GCKSMN1; SMN2AKR1C3 | |
| SCHEMBL29006786 | 0.66 | KEAP1 (0.35) | HRH4GCKAKR1C3AKR1C2 | |
| SCHEMBL6883165 | 0.66 | PTGS2 (0.46) | LOXL2NR1H2ROCK1 | |
| SCHEMBL177999 | 0.66 | TSHR (0.48) | SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200339530-A1 | UREA DERIVATIVES AS INHIBITORS OF ASK1 | HEPAGENE THERAPEUTICS, INC. (VG) | 2020-10-29 | — | — | US | disclosed |
| US-20160303110-A1 | METHODS OF TREATING ABNORMAL MUSCULAR ACTIVITY | AUSPEX PHARMACEUTICALS, INC. (US) | 2016-10-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160303110-A1 | METHODS OF TREATING ABNORMAL MUSCULAR ACTIVITY | PYGM, TNNC1, MUSK | HRH4 3715/4885LOXL2 3648/4885NR1H2 3714/4885 |
| US-20200339530-A1 | UREA DERIVATIVES AS INHIBITORS OF ASK1 | ATF1, ERN1, MAP3K1 | HRH4 4032/4885LOXL2 1871/4885NR1H2 590/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.